In Brief
- Aurigene, the CDMO arm of Dr. Reddy’s Laboratories, signed a long-term Manufacturing and Supply Agreement (MSA) with a confidential global pharmaceutical company.
- The deal covers over 20 drug products—including sterile injectables, biologics, and topical formulations—produced in India for export to the US, Europe, Canada, and emerging markets.
- Marks Aurigene’s major transition from research and development into large-scale commercial manufacturing and supply.
Dr. Reddy’s Laboratories’ CDMO arm, Aurigene Pharmaceutical Services, has signed a long-term Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company. The partnership expands Aurigene’s commercial contract manufacturing capabilities across a portfolio of over 20 pharmaceutical products, including sterile injectables, biologics, and topical formulations. Production will take place at Aurigene’s existing facilities in India, with distribution targeted toward key global markets, including the United States, Europe, Canada, and emerging regions.
While the partnering company remains confidential due to non-disclosure obligations, the deal marks a significant step in Aurigene’s evolution from research and development to large-scale commercial supply.
